New perspective highlights how regulation, technology, and consumer behavior have reshaped the path from physician-only outreach to informed patient engagement.
CHATANOOGA, Tenn., March 24, 2026 /PRNewswire/ — Dr. Danielle Kelvas, MD, founder of DKMD Consulting, today, shared a timely perspective on the evolution of pharmaceutical marketing, tracing its transformation from physician-centered communication to today’s direct-to-consumer landscape and what comes next.
For much of the twentieth century, pharmaceutical marketing operated within a closed system. Physicians served as the sole gatekeepers of prescription information, and outreach was confined to medical conferences, peer-reviewed journals, and in-office engagement. This structure was not simply industry preference. It reflected the regulatory environment that defined what was permissible at the time.
According to Dr. Kelvas, the arc of pharmaceutical marketing over the past century tells a clear and logical story. “We have moved from the unregulated patent medicine era of the early 1900s to physician-centric communication in the mid-century, and now to a model that increasingly includes and informs the patient,” she said. “This is not a sudden disruption. It is the natural progression of a market responding to regulation, access, and information flow.”
A pivotal turning point came in 1997, when updated guidance from the U.S. Food and Drug Administration created a viable pathway for direct-to-consumer advertising. By clarifying requirements for risk disclosure in the broadcast media, the FDA enabled pharmaceutical companies to move beyond dense print-based materials and into television and other mass communication channels.
“The industry did not invent direct-to-consumer marketing in a vacuum,” Dr. Kelvas explained. “It adapted to a new regulatory reality. Once the door opened, it became necessary to engage patients where they are, which increasingly meant in their homes and on their screens.”
For decades prior to this, the industry’s commercial model had been built around a single audience: the healthcare provider. When regulations evolved to allow consumer engagement, companies faced a strategic inflection point. Remaining exclusively focused on physicians would have limited access to a more informed and proactive patient population. Suddenly, consumers were aware of everything from prescription brand names to the risks associated with taking them. This opened a proverbial Pandora’s Box, where commercial advertisements changed from a physician-led dominance to a consumer requested one because they made every prescription look like it was not only lifesaving but also life-changing for patients, their families, and their friends, which is not always the case.
Today’s environment reflects that shift, particularly in fast-growing categories such as weight management. Dr. Kelvas notes that the recent surge in high-visibility advertising is not surprising. “When you combine a significant public health challenge like obesity with a multi-billion-dollar market opportunity, and a legal pathway to reach consumers directly, high-impact campaigns are the predictable outcome,” she said.
At the same time, she acknowledges that the rapid expansion of direct-to-consumer messaging has created friction. “We are seeing a category in transition. The weight loss space is now adopting the same marketing playbook that has been used for years in other verticals like sports, movies, and clothing..You can’t make inflated, hyperbolic claims about medical items anymore. The FTC’s recent taskforce announcement is thankfully cracking down on this. I mean, the pharma commercials we saw during the superbowl and olympics were ridiculous and dangerous.”
As scrutiny increases, Dr. Kelvas believes the industry is entering another phase of recalibration. Ongoing regulatory attention signals a renewed focus on accuracy, transparency, and evidence-based communication.
“Marketing in healthcare has always mirrored the law,” she said. “We adapted in 1906, again in 1962, and in 1997. We will adapt again. The current environment points toward a more balanced and accountable approach.”
Looking ahead, Dr. Kelvas sees the emergence of what she describes as precision marketing. Advances in data analytics, artificial intelligence, and wearable technology are expected to reshape how information is delivered to both patients and providers.
“The future is not about eliminating direct-to-consumer communication,” she added. “It is about refining it. With better data and real-world evidence, we can deliver more meaningful, personalized, and responsible messaging that supports informed decision-making, not manipulative marketing tactics.”
Despite ongoing debate, one outcome remains consistent. Direct-to-consumer advertising often leads patients back to their healthcare providers. “The ultimate irony is that these campaigns frequently encourage patients to initiate conversations with their physicians,” Dr. Kelvas said. “In that sense, the system has come full circle. What began as a physician-only dialogue has evolved into a broader conversation that still ends in the exam room but now includes a more informed patient.”
Dr. Kelvas emphasizes that this evolution represents an opportunity as much as a challenge. “When done responsibly, modern marketing can empower patients, support clinicians, and improve outcomes. The goal is not simply awareness. It is understanding & creating trust.”
About DKMD Consulting
DKMD Consulting, founded by Dr. Danielle Kelvas, MD, provides strategic advisory services at the intersection of healthcare, technology, and communication. The firm works with organizations to navigate regulatory environments, strengthen messaging, and build trust with both providers and patients.
Media Contact:
Brooke Greenwald
brooke@cornerstonepr.net
www.cornerstonepr.net
View original content to download multimedia:https://www.prnewswire.com/news-releases/dkmd-consulting-founder-dr-danielle-kelvas-md-explains-the-evolution-of-pharmaceutical-marketing-from-examining-rooms-to-living-rooms-302722848.html
SOURCE DKMD
